This call will focus on Lilly's recent announcement of results from the Adjoin trial provided durable efficacy in skin and itch outcomes through two years of treatment with both monthly and two-week dosing - nearly 80% of patients with moderate-to-severe atopic dermatitis maintained clear or almost clear skin with lebrikizumab.